US5017482A - Process for producing L-arginine - Google Patents

Process for producing L-arginine Download PDF

Info

Publication number
US5017482A
US5017482A US07/099,798 US9979887A US5017482A US 5017482 A US5017482 A US 5017482A US 9979887 A US9979887 A US 9979887A US 5017482 A US5017482 A US 5017482A
Authority
US
United States
Prior art keywords
arginine
dna
brevibacterium
atcc
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/099,798
Other languages
English (en)
Inventor
Ryoichi Katsumata
Haruhiko Yokoi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Assigned to KYOWA HAKKO KOGYO CO., LTD. reassignment KYOWA HAKKO KOGYO CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: KATSUMATA, RYOICHI, YOKOI, HARUHIKO
Application granted granted Critical
Publication of US5017482A publication Critical patent/US5017482A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/10—Citrulline; Arginine; Ornithine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/84—Brevibacterium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/843—Corynebacterium

Definitions

  • L-arginine can be produced by introducing a recombinant plasmid DNA including a DNA fragment containing a gene of an enzyme relating to the biosynthesis of arginine and derived from Escherichia coli in a strain of the genus Corynebacterium or Brevibacterium by and Culturing the transformant thus obtained (Japanese Published Unexamined Patent Application No. 66989/85).
  • strains with higher L-arginine productivity as compared with pEarg1-carrying strains can be obtained by introducing in a microorganism of the genus Corynebacterium or Brevibacterium a recombinant plasmid containing a gene that relates to the synthesis of at least one enzyme selected from the group consisting of those relating to the biosynthesis of L-arginine in a microorganism of the genus Corynebacterium or Brevibacterium, particularly, N-acetylglutamate kinase (hereinafter abbreviated to AGK), N-acetyl- ⁇ -glutamyl-phosphate reductase (hereinafter abbreviated to AGPR), N-acetylornithine- ⁇ -aminotransferase (hereinafter abbreviated to AOAT), ornithine carbamyltransferase (hereinafter abbreviated to OCT), an enzyme
  • AGK N
  • the present invention relates to a process for producing L-arginine which comprises culturing in a culture medium a microorganism belonging to the genus Corynebacterium or Brevibacterium that carries a recombinant DNA composed of a vector DNA and a DNA fragment derived from a microorganism belonging to the genus Corynebacterium or Brevibacterium and bearing genetic information relating to the synthesis of at least one member selected from the group consisting of AGK, AGPR, AOAT, OCT, an enzyme having an activity to alter AGS-deficient mutants of Escherichia coli which have arginine-requirement to non-arginine-requiring strains, and an enzyme having an activity to alter AOD-deficient mutants of Escherichia coli which have arginine-requirement to non-arginine-requiring strains, and recovering L-arginine formed and accumulated in the culture broth.
  • the present invention is related to the industrial field of bioindustry
  • FIG. 1 illustrates the cleavage maps of pCarg1 and pCarg11 for restriction enzymes, SphI, EcoRI, BamHI, BglII and SalI, and the steps for constructing these plasmids, in which E, Sp, Sa, B and Bg represent the cleavage sites for EcoRI, SphI, SalI, BamHI and BglII, respectively.
  • the sizes of plasmids are expressed in kilobase (kb).
  • the genes coding for arginine-biosynthetic enzymes derived from the chromosomal DNA of Corynebacterium acetoacidophilum ATCC 13870 are included in the parts indicated by the thick solid lines of pCarg1 and pCarg11.
  • the present invention provides a process for producing L-arginine which comprises culturing in a culture medium a microorganism belonging to the genus Corynebacterium or Brevibacterium that carries a recombinant DNA composed of a vector DNA and a DNA fragment derived from a microorganism belonging to the genus Corynebacterium or Brevibacterium and bearing genetic information relating to the synthesis of one or more L-arginine-biosynthetic enzymes; accumulating L-arginine in the culture broth; and recovering L-arginine therefrom.
  • the genetic information relating to the synthesis of an L-arginine-biosynthetic enzyme relates to, for example, the synthesis of at least one of AGK, AGPR, AOAT, OCT, an enzyme having an activity to alter AGS-deficient mutants of Escherichia coli which have arginine-requirement to non-arginine-requiring strains, and an enzyme having an activity to alter AOD-deficient mutants of Escherichia coli which have arginine-requirement to non-arginine-requiring strains.
  • any of the strains known as glutamic acid-producing coryneform bacteria may be used as the host microorganism belonging to the genus Corynebacterium or Brevibacterium. Preferred examples are as follows.
  • Corynebacterium acetoacidophilum ATCC 13870
  • mutants capable of producing L-arginine such as those resistant to amino acid analogues and other known mutants, may be used as the host microorganism.
  • any glutamic acid-producing coryneform bacterium having the corresponding enzyme activity may be used.
  • wild-type strains of the genus Corynebacterium or Brevibacterium, and L-arginine-producing mutants derived therefrom are employed.
  • Chromosomal DNA of these strains can be isolated, as disclosed in Japanese Published Unexamined Patent Application No. 126789/83, by treating the cells that have been treated with penicillin during culturing with lysozyme and a surface-active agent for bacteriolysis, and removing proteins by a conventional method, followed by precipitation with ethanol.
  • any plasmid which is autonomously replicable in microorganisms belonging to the genus Corynebacterium or Brevibacterium may be used.
  • plasmids are pCG1 (Japanese Published Unexamined Patent Application No. 134500/82), pCG2 (Japanese Published Unexamined Patent Application No. 35197/83), pCG4 and pCG11 (Japanese Published Unexamined Patent Application No. 183799/82), pCE51, pCE52 and pCE53 [Mol. Gen.
  • plasmid vectors can be isolated and purified as ccc-DNA by treating the cells with lysozyme and a surface-active agent for bacteriolysis, preparing the cleared lyzate therefrom, precipitating DNAs with polyethylene glycol, and subjecting the DNAs thus obtained to cesium chloride/ethidium bromide density-gradient centrifugation.
  • the recombinant DNA composed of a vector plasmid and a DNA fragment containing the gene encoding an enzyme relating to the biosynthesis of arginine can be obtained as a mixture with various recombinant DNAs according to the ordinary procedures, by cleaving the chromosomal DNA and the vector plasmid DNA with a restriction enzyme followed by, if necessary, treatment of the cleaved ends with a terminal transferase or DNA polymerase, and ligating both DNAs by the action of a DNA ligase [Methods in Enzymology, 68 (1979)].
  • the mixture of ligated DNAs thus obtained is used to transform a mutant strain of the genus Corynebacterium or Brevibacterium deficient in an enzyme relating to the biosynthesis of arginine, and a transformant in which the deficiency is complemented is selected. Transformation of a strain of the genus Corynebacterium or Brevibacterium can be carried out by the method using protoplasts (Japanese Published Unexamined Patent Application Nos. 186492/82 and 186489/82, specifically described in Examples).
  • the recombinant plasmid composed of a vector DNA and a DNA fragment containing the gene of the enzyme that relates to the biosynthesis of arginine can be obtained from the transformant by recombinant DNA techniques.
  • a host-vector system on which recombinant DNA techniques have already been established such as that of Escherichia coli may be used in place of the system by which the recombinant DNA is directly selected using a strain of the genus Corynebacterium or Brevibacterium as described above. That is, in vitro reaction product of the ligation of a vector DNA of Escherichia coli and a DNA fragment containing the said gene is used to transform a mutant of Escherichia coli deficient in the gene of the enzyme that relates to the biosynthesis of arginine. A transformant in which the deficiency is complemented is selected, and a cloned DNA fragment containing the said gene is obtained from the transformant.
  • the cloned DNA fragment is recombined with the vector DNA of the genus Corynebacterium or Brevibacterium in vitro and the recombinant DNA thus obtained is used to transform a strain of the genus Corynebacterium or Brevibacterium.
  • a recombinant DNA containing a wild-type gene encoding an arginine-biosynthetic enzyme can be obtained by using the chromosomal DNA of a wild-type strain of the genus Corynebacterium or Brevibacterium.
  • the recombinant DNA is introduced into a suitable strain of the genus Corynebacterium or Brevibacterium through transformation, whereby the arginine productivity of the strain can be increased.
  • Such recombinant plasmids containing a mutant gene free from control by arginine can be obtained by using the chromosomal DNA of a mutant strain containing the gene of AGK insensitive to the inhibition by L-arginine, which is selected based on the resistance to L-arginine analogues (e.g., D-arginine), according to the same method as in the case of the wild-type gene as described in Agric. Biol. Chem., 43, 1899 (1979).
  • these recombinant plasmids may be obtained by in vitro mutagenesis of a recombinant plasmid containing a wild-type gene according to the method shown in Mol. Gen. Genet., 145, 101 (1978), or by in vivo mutagenesis of a strain carrying a recombinant plasmid containing a wild-type gene
  • the thus obtained recombinant plasmid containing a wild-type or mutant gene relating to the biosynthesis of arginine can be introduced into a strain of the genus Corynebacterium or Brevibacterium by the transformation method using a protoplast as mentioned above.
  • Production of L-arginine by such a transformant carrying the recombinant plasmid can be carried out by the same method as in a conventional process for producing L-arginine by fermentation.
  • the transformant is cultured in an ordinary culture medium containing carbon sources, nitrogen sources, inorganic compounds, amino acids, vitamins and other nutrients under aerobic conditions while adjusting the temperature, pH, etc., and L-arginine accumulated in the culture medium is recovered therefrom.
  • various carbohydrates such as glucose, glycerol, fructose, sucrose, maltose, mannose, starch, starch hydrolyzate and molasses; polyalcohols; and various organic acids such as pyruvic acid, fumaric acid, lactic acid and acetic acid can be used.
  • hydrocarbons, alcohols, etc. can be used depending upon the assimilability of the strain employed.
  • blackstrap molasses is preferably used.
  • ammonia As the nitrogen source, ammonia; various inorganic and organic ammonium salts such as ammonium chloride, ammonium sulfate, ammonium carbonate and ammonium acetate; urea and other nitrogen-containing substances; and nitrogen-containing organic substances such as peptone, NZ-amine, meat extract, yeast extract, corn steep liquor, casein hydrolyzate, fish meal or its digested product, defatted soybean cake or its digested product and chrysalis hydrolyzate can be used.
  • various inorganic and organic ammonium salts such as ammonium chloride, ammonium sulfate, ammonium carbonate and ammonium acetate
  • urea and other nitrogen-containing substances such as peptone, NZ-amine, meat extract, yeast extract, corn steep liquor, casein hydrolyzate, fish meal or its digested product, defatted soybean cake or its digested product and chrysalis hydrolyzate
  • dipotassium hydrogenphosphate potassium dihydrogenphosphate
  • ammonium sulfate ammonium chloride
  • magnesium sulfate sodium chloride
  • ferrous sulfate manganese sulfate
  • calcium carbonate etc.
  • Amino acids and vitamins need not be added if they are supplied to the medium as components of the nutrients mentioned above.
  • Cultivation is carried out under aerobic conditions, for example, by shaking culture or by aeration-stirring culture, preferably at a temperature in the range of 20° to 40° C.
  • the pH of the medium is preferably maintained around neutrality during the cultivation.
  • L-arginine is accumulated in the medium usually by culturing for one to five days.
  • the cells After being cultured, the cells are removed from the culture broth, and the resulting culture liquor is treated in a known manner (e.g., treatment with activated carbon or ion-exchange resins) to recover L-arginine.
  • a known manner e.g., treatment with activated carbon or ion-exchange resins
  • L-arginine can thus be produced in higher yields by using a strain of the genus Corynebacterium or Brevibacterium carrying a recombinant plasmid that contains the gene encoding an enzyme relating to the biosynthesis of arginine derived from glutamic acid-producing coryneform bacteria, as compared with the case where strains which do not carry such a recombinant plasmid are used.
  • strains include Corynebacterium glutamicum K64 (FERM BP-1114) and Corynebacterium glutamicum K65 (FERM BP-1115), which were deposited with the Fermentation Research Institute, Agency of Industrial Science and Technology (FRI) on July 24, 1986.
  • FERM BP-1114 Corynebacterium glutamicum K64
  • FERM BP-1115 Corynebacterium glutamicum K65
  • the optical density at 660 nm (OD; hereinafter the optical density is measured at 660 nm unless otherwise specified) was determined with a Tokyo Koden colorimeter, and when the OD reached 0.2, penicillin G was added to a concentration of 0.5 unit/ml. Culturing was further continued until the OD reached 0.6.
  • the grown cells were collected from the culture broth and washed with TES buffer solution [0.03M Tris(hydroxymethyl)aminomethane (hereinafter referred to as Tris), 0.005M disodium ethylenediaminetetraacetate (hereinafter referred to as EDTA) and 0.05M NaCl; pH 8.0].
  • Tris Tris(hydroxymethyl)aminomethane
  • EDTA disodium ethylenediaminetetraacetate
  • NaCl 0.05M NaCl
  • the washed cells were suspended in 10 ml of a lysozyme solution (25% sucrose, 0.1M NaCl, 0.05M Tris and 0.8 mg/ml lysozyme; pH 8.0), and subjected to reaction at 37° C. for four hours.
  • High molecular chromosomal DNA was isolated from the collected cells according to the method of Saito, et al. [Biochem. Biophys. Acta, 72, 619 (1963)].
  • Escherichia coli K12 WA802 carrying host-specific restriction-deficient mutation was mutated by using 400 ⁇ /ml N-methyl-N'-nitro-N-nitrosoguanidine (NTG) according to a conventional method [Experiment in Molecular Genetics, P. 125, Coldspring Harbor Laboratory (1972)], and arginine-requiring strains were selected according to the concentration method for an auxotroph using penicillin [Experiment in Molecular Genetics, P. 230, Coldspring Harbor Laboratory (1972)].
  • the mutant genes of these arginine-requiring strains were identified by measuring the activity of each enzyme relating to the biosynthesis of arginine according to the method described in Eur. J.
  • EA-1 was obtained as an AGS-deficient mutant strain
  • EA-21 as an AGK-deficient mutant strain
  • EA-4 as an AOD-deficient mutant strain.
  • Cloning was carried out by using a host-vector system of Escherichia coli.
  • pBR322 resistant to ampicillin and tetracyline
  • 10 units of restriction enzyme SphI product of Boehringer Mannheim GmbH
  • SphI was added to 200 ⁇ l of a reaction solution for SphI (6 mM Tris, 125 mM NaCl, 6 mM MgCl 2 , 6 mM ⁇ -mercaptoethanol and 0.01% Triton X-100; pH 7.5) containing 1 ⁇ g of pBR322 plasmid DNA and 3 ⁇ g of the chromosomal DNA of Corynebacterium acetoacidophilum ATCC 13870 prepared in (1) above, and the mixture was subjected to reaction at 37° C.
  • EA-21 strain was inoculated in 50 ml of L medium (10 g/l Bacto-Tryptone, 5 g/l yeast extract, 1 g/l glucose and 5 g/l NaCl; pH 7.2) and cultured at 37° C. until the OD reached 0.5.
  • L medium 10 g/l Bacto-Tryptone, 5 g/l yeast extract, 1 g/l glucose and 5 g/l NaCl; pH 7.2
  • the culture broth was cooled on ice for ten minutes, and then subjected to centrifugation.
  • the cells collected by centrifugation were suspended in 20 ml of cooled 0.1M CaCl 2 solution, and the suspension was allowed to stand at 0° C. for 20 minutes.
  • the cells were again collected by centrifugation and resuspended in 0.5 ml of 0.1M CaCl 2 , and the suspension was allowed to stand at 0° C.
  • Plasmid DNAs were isolated from the cultured cells of the transformants thus grown by the method of Ann, et al. [J. Bacteriol., 140, 400 (1979)].
  • pCarg1 had a structure wherein an SphI DNA fragment of 7 kb was inserted at the single SphI cleavage site of pBR322.
  • mutants obtained by transforming AGS-deficient mutant strain EA-1 and AOD-deficient mutant strain EA-4 both are arginine- and methionine-requiring derived from Escherichia coli K12 strain and prepared in (2) above with pCarg1 in the same manner as above and selecting based on ampicillin resistance had no arginine-requirement.
  • pCarg1 also contains the genes coding for enzymes having activities to alter AGS-deficient mutants and AOD-deficient mutants of Escherichia coli which have arginine-requirement to non-arginine-requiring strains.
  • WA802 strain which carries pCarg1 and WA802 strain which does not carry pCarg1 were examined for AGK activity, AGPR activity, AOAT activity and OCT activity according to the method of Baumberg, et al. [J. Gen. Microbiol., 69, 365 (1971)], the method of Vogel, et al. [Methods in Enzymology, 17 (Part A), 255 (1970)], the method of Vogel, et al. [Methods in Enzymology, 17 (Part A), 260 (1970)] and the method of Prescott, et al. [Anal. Biochem., 32, 408 (1969)], respectively.
  • WA802 strain carrying pCarg1 exhibited more than three times higher activity for each enzyme activity, which indicates that pCarg1 contains the genes coding for AGK, AGPR, AOAT and OCT.
  • pCarg1 carries the genes derived from Corynebacterium acetoacidophilum ATCC 13870 and coding for AGK, AGPR, AOAT, OCT and enzymes having activities to alter AGS-deficient mutants and AOD-deficient mutants of Escherichia coli which have arginine-requirement to non-arginine-requiring strains.
  • a shuttle vector pCarg11 capable of replicating in both Escherichia coli and glutamic acid-producing coryneform bacteria was prepared by recombination of pCarg1 obtained above with vector plasmid pCG11 which is replicable in glutamic acid-producing coryneform bacteria.
  • pCH11 is a plasmid vector replicable in microorganisms of the genera Corynebacterium and Brevibacterium, which carries a streptomycin-spectinomycin resistance gene.
  • pCarg11 was constructed by the process described below.
  • pCH11 was isolated from Corynebacterium glutamicum ATCC 31833 carrying pCG11 according to the method disclosed in Japanese Published Unexamined Patent Application No. 134500/82.
  • a reaction solution for restriction enzyme BglII 10 mM Tris, 100 mM NaCl and 10 mM MgCl 2 ; pH 7.5
  • BglII product of Takara Shuzo Co., Ltd.
  • Both digestion reaction mixtures were mixed together, and 40 ⁇ l of T4 ligase buffer solution at a 10-fold concentration, 4 ⁇ l of 100 mM ATP, 150 ⁇ l of water and 300 units of T4 ligase (product of Takara Shuzo Co., Ltd.) were added thereto.
  • the mixture was subjected to reaction at 12° C. for 16 hours. Transformation of Escherichia coli EA-21 was carried out in the same manner as in (3) above using this ligase reaction mixture, and the transformants thus formed were spread on the Davis' minimal agar plate medium containing 30 ⁇ g/ml methionine and 100 ⁇ g/ml spectinomycin.
  • Plasmid DNA was isolated from a spectinomycin-resistant and non-arginine-requiring transformant grown on this plate medium according to the method of Ann, et al. [J. Bacteriol., 140, 400 (1979)]. Analysis by digestion with various restriction enzymes, followed by agarose gel electrophoresis, revealed that this plasmid had a structure in which pCG11 and pCarg1 were ligated at the single BglII cleavage site of the former and the single BamHI cleavage site of the latter (refer to FIG. 1). This plasmid was named pCarg11.
  • pCarg11 was then used for transforming Corynebacterium glutamicum ATCC 31833 according to the methods described in Japanese Published Unexamined Patent Application Nos. 186492/82 and 186489/82.
  • the cells of ATCC 31833 strain were cultured in NB medium, and 0.4 ml of the obtained seed culture was inoculated in 40 ml of SSM medium, and subjected to shaking culture at 30° C. When the OD reached 0.15, penicillin G was added to a final concentration of 0.5 unit/ml. Culturing was further continued, and the grown cells were collected when the OD reached about 0.6.
  • the collected cells were suspended in 5 ml of RCGP medium [5 g/l glucose, 5 g/l Casamino acid, 2.5 g/l yeast extract, 3.5 g/l K 2 HPO 4 , 1.5 g/l KH 2 PO 4 , 0.41 g/l MgCl 2 .6H 2 O, 10 mg/l FeSO 4 .7H 2 O, 2 mg/l MnSO 4 .4-6H 2 O, 0.9 mg/l ZnSO 4 .7H 2 O, 0.04 mg/l (NH 4 ) 6 Mo 7 O 24 .4H 2 O, 30 ⁇ g/l biotin, 2 mg/l thiamine hydrochloride, 135 g/l disodium succinate and 30 g/l polyvinylpyrrolidone (M.W.: 10,000); pH 7.6] containing 1 mg/ml lysozyme to make up about 10 9 cells per milliliter, and the suspension was transferred into an L-tube and subjected to gentle shaking culture
  • the protoplast suspension (0.5 ml) was taken in a small test tube and centrifuged for five minutes at 2,500 ⁇ g to separate the protoplasts.
  • the protoplasts were then suspended in 1 ml of TSMC buffer solution (10 mM MgCl 2 , 30 mM CaCl 2 , 50 mM Tris and 400 mM sucrose; pH 7.5) and washed by centrifugation, and the washed cells were resuspended in 0.1 ml of TSMC buffer solution.
  • TSMC buffer solution 100 ⁇ l of a 1:1 mixture of TSMC buffer solution at a two-fold concentration and pCarg11 plasmid DNA solution was added to the suspension, and 1.0 ml of TSMC buffer solution containing 20% polyethyleneglycol (PEG) 6000 (product of Nakarai Chemicals, Ltd.) was further added thereto. After three minutes, the resulting mixture was centrifuged for five minutes at 2,500 ⁇ g to remove the supernatant. The precipitated protoplasts were suspended in 1 ml of RCGP medium (pH 7.4), and the suspension was subjected to gentle shaking at 30° C. for two hours. This protoplast suspension (0.3 ml) was spread on RCGP agar medium (RCGP medium containing 1.6% agar; pH 7.4) containing 400 ⁇ g/ml spectinomycin, and cultured at 30° C. for eight days.
  • PEG polyethyleneglycol
  • the spectinomycin-resistant transformant thus grown was subjected to shaking culture in 400 ml of SSM medium. Penicillin G was added to a final concentration of 0.5 unit/ml when the OD reached 0.15, and shaking culture was continued until the OD reached 0.65. Then, the cells collected from the culture broth were washed with TES buffer solution, suspended in 10 ml of a lysozyme solution, and subjected to reaction at 37° C. for four hours.
  • pellets were recovered by centrifugation at 1,500 ⁇ g for 10 minutes and gently redissolved in 5 ml of TES buffer solution. 2.0 ml of 1.5 mg/ml ethidium bromide solution was added thereto, and cesium chloride was further added and gently dissolved to adjust the density of the solution to 1.580.
  • the solution thus obtained was subjected to ultracentrifugation at 105,000 ⁇ g at 18° C. for 48 hours, and a closed circular DNA was detected as a band at a high density level at the lower position of the centrifuge tube under UV irradiation. This band was recovered from the side of the centrifuge tube by means of a syringe, whereby plasmid was isolated.
  • the obtained fraction was treated five times with an equal volume of an isopropyl alcohol solution (9:1 mixture of isopropyl alcohol and TES buffer solution by volume further containing a saturated amount of cesium chloride) to remove ethidium bromide by extraction, and the treated solution was then dialyzed against TES buffer solution to obtain a plasmid DNA.
  • the cells collected from the culture broth were washed with buffer solution A (10 mM Tris and 1 mM dithiothreitol; pH 7.2) and suspended in 10 ml of buffer solution A.
  • the suspension was subjected to ultrasonic treatment for 20 minutes on Sonicator (TOMY Seiko Co., Ltd.; Intensity Range: 7) to disrupt the cells in the suspension, and the disrupted cell suspension was centrifuged at 16,000 rpm for 40 minutes (RPR 20-2 rotor; Hitachi, Ltd.). The supernatant was recovered and dialyzed twice against 1 liter of buffer solution A at 4° C. for six hours to remove low molecular substances.
  • buffer solution A 10 mM Tris and 1 mM dithiothreitol; pH 7.2
  • the suspension was subjected to ultrasonic treatment for 20 minutes on Sonicator (TOMY Seiko Co., Ltd.; Intensity Range: 7) to disrupt the cells in the suspension, and the disrupted cell suspension was
  • the crude enzyme extracts thus obtained were examined for AGK activity according to the method of Baumberg, et al. [J. Gen. Microbiol., 69, 365 (1971)] and for AOAT activity according to the method of Vogel, et al. [Methods in Enzymology, 17 (Part A), 260 (1970)].
  • the enzyme extract obtained from ATCC 31833 strain carrying pCarg11 exhibited 30 times higher activity for AGK and 10 times higher activity for AOAT as compared with the enzyme extract obtained from ATCC 31833 strain which does not carry pCarg11. This fact indicates that the genes in pCarg11 can be expressed in glutamic acid-producing coryneform bacteria.
  • the pCarg11-carrying transformant thus obtained has been deposited with FRI as Corynebacterium glutamicum K64 (FERM BP-1114).
  • a mutant plasmid which is capable of increasing the L-arginine productivity of a host microorganism was prepared by direct treatment of pCarg11 DNA with hydroxylamine [Mol. Gen. Genet., 145, 101 (1978)] as described below.
  • pCarg11 was isolated from Corynebacterium glutamicum K64 (FERM BP-1114) according to the method described in (4) above. pCarg11 (2 ⁇ g) was added to 300 ⁇ l of a mutating solution (50 mM NaH 2 PO 4 , 400 mM hydroxylamine hydrochloride and 0.5 mM EDTA; pH 6.0), and the mixture was subjected to reaction at 75° C. for 60 minutes and dialyzed against TES buffer solution.
  • a mutating solution 50 mM NaH 2 PO 4 , 400 mM hydroxylamine hydrochloride and 0.5 mM EDTA; pH 6.0
  • the dialyzate thus obtained (100 ⁇ l) was used to transform Corynebacterium glutamicum ATCC 31833 in the same manner as in (4) above, and the obtained spectinomycin-resistant strains were tested for arginine productivity in the following manner.
  • FIG. 1 illustrates the steps for constructing pCarg1 and pCarg11.
  • Table 1 shows the results of L-arginine productivity test on the strains carrying pCarg11 or pCarg110, and the strain carrying pEarg1 (Japanese Published Unexamined Patent Application No. 66989/85) prepared in a way similar to that described in (4) above.
  • Corynebacterium herculis ATCC 13868 and Brevibacterium flavum ATCC 14067 were transformed by using pCarg11 and pCarg110 in the same manner as in (4) above. Plasmids were isolated from the obtained spectinomycin-resistant transformants in the same manner as in (4), and their structures were analyzed by digestion with various restriction enzymes, followed by agarose gel electrophoresis. It was confirmed that these transformants carried pCarg11 or pCarg110.

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US07/099,798 1986-09-22 1987-09-22 Process for producing L-arginine Expired - Lifetime US5017482A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP61224189A JPH0728749B2 (ja) 1986-09-22 1986-09-22 Ｌ−アルギニンの製造法
JP61-224189 1986-09-22

Publications (1)

Publication Number Publication Date
US5017482A true US5017482A (en) 1991-05-21

Family

ID=16809916

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/099,798 Expired - Lifetime US5017482A (en) 1986-09-22 1987-09-22 Process for producing L-arginine

Country Status (5)

Country Link
US (1) US5017482A (ja)
EP (1) EP0261627B1 (ja)
JP (1) JPH0728749B2 (ja)
KR (1) KR900004425B1 (ja)
DE (1) DE3785530T2 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187268A (en) * 1988-08-20 1993-02-16 United States Of America Gene encoding an anti-complement protein from vaccinia
US5284757A (en) * 1989-01-12 1994-02-08 Ajinomoto Company, Inc. Process for producing l-arginine by fermentation with brevibacterium or corynebacterium
US5374542A (en) * 1991-08-26 1994-12-20 Kyowa Hakko Kogyo Co., Ltd. Process for producing 4-hydroxy-L-proline
US5487986A (en) * 1994-03-10 1996-01-30 Genzyme Corporation Method for increasing plasmid yield
US5595894A (en) * 1990-11-22 1997-01-21 Kyowa Hakko Kogyo Co. Ltd. Process for stably maintaining recombinant plasmids in serine auxotrophic microorganisms belonging to the genus Corynebacterium or Brevibacterium
US20030124686A1 (en) * 1998-11-02 2003-07-03 Ajinomoto Co. Inc. Method for producing L-arginine
US20050026259A1 (en) * 2000-07-06 2005-02-03 Ajinomoto Co., Inc. L-arginine producing Escherichia coli and method of producing L-arginine
US20090123980A1 (en) * 2004-09-28 2009-05-14 Kyowa Hakko Kogyo Co., Ltd. Process for producing l-arginine, l-ornithine or l-citrulline

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3047832U (ja) * 1997-10-08 1998-04-28 有限会社エイ・エヌ・シー ハンドフリー型通話装置
US6184036B1 (en) * 1998-07-17 2001-02-06 E. I. Du Pont De Nemours And Company Ornithine biosynthesis enzymes
US6255086B1 (en) 1999-02-01 2001-07-03 Ajinomoto Co., Inc. Carbamoyl-phosphate synthetase gene of coryneform bacteria and method for producing L-arginine
US20030124685A1 (en) * 1999-02-01 2003-07-03 Yoko Kuwabara Carbamoyl-phosphate synthetase gene of coryneform bacteria and method for producing l-arginine
DE60034843T2 (de) * 1999-06-03 2008-01-17 Ajinomoto Co., Inc. Verfahren zur Herstellung von L-arginin
US7160705B2 (en) 2000-04-28 2007-01-09 Ajinomoto Co., Inc. Arginine repressor deficient strain of coryneform bacterium and method for producing L-arginine
KR101481782B1 (ko) * 2012-12-28 2015-01-13 대상 주식회사 Gogat의 불활성화에 의한 아미노산 고생산능 변이 균주
KR101835935B1 (ko) 2014-10-13 2018-03-12 씨제이제일제당 (주) L-아르기닌을 생산하는 코리네박테리움 속 미생물 및 이를 이용한 l-아르기닌의 제조 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775623A (en) * 1983-09-24 1988-10-04 Kyowa Khkko Kogyo Co., Ltd. Process for producing L-arginine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55148093A (en) * 1979-05-02 1980-11-18 Ajinomoto Co Inc Preparation of l-arginine
JPS575693A (en) * 1980-06-13 1982-01-12 Ajinomoto Co Inc Production of l-arginine through fermentation process
JPS5867699A (ja) * 1981-10-16 1983-04-22 Ajinomoto Co Inc プラスミド
WO1984003301A1 (en) * 1983-02-17 1984-08-30 Kyowa Hakko Kogyo Kk Process for preparing amino acid

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775623A (en) * 1983-09-24 1988-10-04 Kyowa Khkko Kogyo Co., Ltd. Process for producing L-arginine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cunin, 1983, In: Amino Acids , Hermann and Somerville (eds), Addison Wesley Publ., Co., London, pp. 67 69. *
Cunin, 1983, In: Amino Acids, Hermann and Somerville (eds), Addison-Wesley Publ., Co., London, pp. 67-69.
Kharitonov et al., Chemical Abstracts, Vol. 105(21), Abst. 185243j; In: Mol. Genet. Mikrobiol. Virusol., 1986, vol. 8(9) pp. 29 33 (Russian). *
Kharitonov et al., Chemical Abstracts, Vol. 105(21), Abst.#185243j; In: Mol. Genet. Mikrobiol. Virusol., 1986, vol. 8(9) pp. 29-33 (Russian).

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187268A (en) * 1988-08-20 1993-02-16 United States Of America Gene encoding an anti-complement protein from vaccinia
US5284757A (en) * 1989-01-12 1994-02-08 Ajinomoto Company, Inc. Process for producing l-arginine by fermentation with brevibacterium or corynebacterium
US5595894A (en) * 1990-11-22 1997-01-21 Kyowa Hakko Kogyo Co. Ltd. Process for stably maintaining recombinant plasmids in serine auxotrophic microorganisms belonging to the genus Corynebacterium or Brevibacterium
US5624828A (en) * 1990-11-22 1997-04-29 Kyowa Hakko Kogyo Co. Ltd. Process for producing L-tryptophan in serine auxotrophic microorganisms belonging to the genus corynebacterium or brevabacterium
US5374542A (en) * 1991-08-26 1994-12-20 Kyowa Hakko Kogyo Co., Ltd. Process for producing 4-hydroxy-L-proline
US5487986A (en) * 1994-03-10 1996-01-30 Genzyme Corporation Method for increasing plasmid yield
WO1996006925A1 (en) * 1994-03-10 1996-03-07 Genzyme Corporation Method for increasing plasmid yield
AU699919B2 (en) * 1994-03-10 1998-12-17 Genzyme Corporation Method for increasing plasmid yield
US20030124686A1 (en) * 1998-11-02 2003-07-03 Ajinomoto Co. Inc. Method for producing L-arginine
US20050026259A1 (en) * 2000-07-06 2005-02-03 Ajinomoto Co., Inc. L-arginine producing Escherichia coli and method of producing L-arginine
US7052884B2 (en) * 2000-07-06 2006-05-30 Ajinomoto Co., Inc. L-arginine producing Escherichia coli and method of producing L-arginine
CN100365115C (zh) * 2000-07-06 2008-01-30 味之素株式会社 产l-精氨酸的大肠杆菌及生产l-精氨酸的方法
US20090123980A1 (en) * 2004-09-28 2009-05-14 Kyowa Hakko Kogyo Co., Ltd. Process for producing l-arginine, l-ornithine or l-citrulline
US7741081B2 (en) 2004-09-28 2010-06-22 Kyowa Hakko Bio Co., Ltd. Process for producing L-arginine, L-ornithine or L-citrulline

Also Published As

Publication number Publication date
EP0261627B1 (en) 1993-04-21
EP0261627A3 (en) 1989-10-04
JPH0728749B2 (ja) 1995-04-05
DE3785530D1 (de) 1993-05-27
KR880004091A (ko) 1988-06-01
EP0261627A2 (en) 1988-03-30
JPS6379597A (ja) 1988-04-09
DE3785530T2 (de) 1993-11-18
KR900004425B1 (ko) 1990-06-25

Similar Documents

Publication Publication Date Title
EP0136359B1 (en) Process for preparing l-histidine
US5605818A (en) Process for producing L-tryptophan, L-tyrosine or L-phenylalanine
KR900004426B1 (ko) L-티로신의 제조방법
US5017482A (en) Process for producing L-arginine
JPH06102028B2 (ja) アミノ酸の製造法
EP0030727A2 (en) Method for producing L-valine by fermentation and method for producing a new microorganism of the genus Escherichia
US5498532A (en) Process for producing amino acids
US4775623A (en) Process for producing L-arginine
US5407824A (en) Recombinant coryneform bacterium for producing L-tryptophan
US5563052A (en) Process for producing L-tryptophan
CA1306963C (en) Process for producing l-threonine and l-isoleucine
US4968609A (en) Coryneform bacteria carrying recombinant DNA and a process for producing aromatic amino acids using said bacteria
US5426050A (en) Plasmid vectors for expression of genes in coryneform bacteria
EP0259858B1 (en) Process for producing amino acids
CA1218025A (en) Process for producing histidine
US5595894A (en) Process for stably maintaining recombinant plasmids in serine auxotrophic microorganisms belonging to the genus Corynebacterium or Brevibacterium
EP0233581A2 (en) Process for producing L-threonine or L-isoleucine
US5017481A (en) Coryneform bacteria carrying recombinant DNA and process for producing an aromatic amino acid by using the same
CA1283070C (en) Process for production of l-phenylalanine by fermentation
EP0264914A2 (en) Process for producing L-phenylalanine
JPH0611230B2 (ja) 新規組換え体プラスミド

Legal Events

Date Code Title Description
AS Assignment

Owner name: KYOWA HAKKO KOGYO CO., LTD., 6-1, OHTEMACHI ITCHOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:KATSUMATA, RYOICHI;YOKOI, HARUHIKO;REEL/FRAME:004780/0378

Effective date: 19870908

Owner name: KYOWA HAKKO KOGYO CO., LTD.,JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KATSUMATA, RYOICHI;YOKOI, HARUHIKO;REEL/FRAME:004780/0378

Effective date: 19870908

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12